Trav6d-3 Inhibitors
Trav6d-3 inhibitors are a class of chemical compounds that interact specifically with the Trav6d-3 protein or receptor to modulate its biological activity. These inhibitors typically achieve this by binding to the active site of the Trav6d-3 protein, blocking the access of its natural substrates or preventing its normal biological function. In some cases, Trav6d-3 inhibitors may bind to allosteric sites-regions other than the active site-causing conformational changes in the protein that indirectly reduce its activity. The mechanism by which these inhibitors function depends heavily on the specific structure of the Trav6d-3 protein, as well as the molecular architecture of the inhibitor itself. These inhibitors may exhibit a variety of non-covalent interactions, such as hydrogen bonding, ionic interactions, or hydrophobic contacts, which stabilize the binding of the inhibitor to the protein.
Structurally, Trav6d-3 inhibitors can be highly diverse, ranging from small organic molecules to larger, more complex compounds. The design of these inhibitors often incorporates key chemical features such as aromatic rings, heteroatoms, or polar groups to optimize interactions with the target protein. For example, hydrophobic portions of the inhibitor may allow it to interact with non-polar regions of the Trav6d-3 protein, while polar functional groups, like hydroxyl or amine groups, can form hydrogen bonds with polar regions of the protein. Additionally, the overall size, shape, and flexibility of the inhibitor are critical factors in determining how well it fits into the binding site and its binding strength. The physicochemical properties of Trav6d-3 inhibitors-such as their solubility, lipophilicity, and molecular weight-are essential considerations during their design, as they impact not only how the inhibitor interacts with Trav6d-3 but also how it behaves in different biological environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators in many signaling pathways. Since PI3K can activate several downstream proteins including Trav6d-3 by initiating signaling cascades, the inhibition of PI3K by Wortmannin could lead to a decrease in Trav6d-3 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another well-known inhibitor of PI3K. By inhibiting PI3K, LY294002 prevents the activation of downstream signaling pathways that could lead to the activation of Trav6d-3, thereby functionally inhibiting Trav6d-3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin), which is part of the PI3K/AKT/mTOR pathway, a critical signaling pathway for cell growth and proliferation. Inhibition of mTOR can lead to reduced signaling through pathways that potentially involve Trav6d-3, thereby inhibiting its function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting certain kinases that are necessary for the activation of pathways involving Trav6d-3, Staurosporine can indirectly inhibit the function of Trav6d-3. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in cell cycle regulation, and their inhibition can disrupt processes that potentially involve Trav6d-3, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of the MAPK/ERK pathway. Since the MAPK/ERK pathway can regulate various proteins, inhibition of MEK by PD98059 may lead to decreased activation of Trav6d-3 through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress and inflammatory responses. By inhibiting JNK, SP600125 can alter signaling pathways that may involve Trav6d-3, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can disrupt signaling pathways that potentially involve Trav6d-3, leading to reduced Trav6d-3 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibition of MEK1/2 by U0126 can lead to decreased ERK activation and, consequently, could inhibit the function of Trav6d-3 involved in this pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-Kit, and PDGFR. As tyrosine kinases are involved in various signaling pathways, the inhibition of these kinases by Imatinib could result in reduced activity of proteins such as Trav6d-3, which may be regulated by these pathways. | ||||||